Home Latest Articles
Latest Articles
  • Jiahao HU, Qi KANG, Lin ZHU, Yuhan LIU, Xiaohui HOU, Jiangjiang HE, Chunlin JIN
    World Clinical Drug. 2022, 43(2): 109-114.

    With the release of the list of rare disease in China, the economic evaluation of drug use for rare disease is also gradually advancing. Rare disease is characterized by insufficient cognition and basic research, difficult diagnosis, difficult evaluation of therapeutic effect and difficult patients recruitments. Clinical studies on the use of rare diseases also have problems such as non-random design and short follow-up period, which increase the difficulty of pharmacoeconomic evaluation. In pharmacoeconomic evaluation of drugs for rare disease, problems may occur, such as difficulty in selecting reference drugs, uncertainty in model structure, difficulty and high uncertainty in obtaining efficacy data, safety data, cost and health utility parameters. Based on the above problems and challenges, this paper put forward countermeasures that could be taken by all stakeholders in China, so as to make a more objective and reasonable economic evaluation of drug use for rare disease, and reduced the uncertainty of results and decision-making uncertainty of medical insurance departments.

  • Ni YUAN, Guangsheng LIANG, Hanyu CHANG, Meiqi WANG, Xiaoyan GUAN, Jun HU
    World Clinical Drug. 2022, 43(2): 115-123.

    Gene therapy, as a new type of treatment, has been applied to rare disease and other difficult medical problems, bringing hopes to patients with rare disease. However, three major challenges including difficulty in evidence generating or data collection, value evaluation (including pricing and budget impact analysis) and difficulties in payment and reimbursement. Therefore, formulating a reasonable payment was essential to protect the health of patients and improve the accessibility of gene therapy. Taking gene therapy drugs for rare disease as an example, this article summarized the current payment models and some practices in developed countries, in order to discuss how to pay for expensive gene therapy drugs within the limited budget constraints.

  • Lin ZHU, Jiahao HU, Qi KANG, Yifan XU, Chunlin JIN
    World Clinical Drug. 2022, 43(2): 124-129.

    Patient-reported outcomes (PROs) refers to reports directly obtained from patients about their health status, physical function and treatment experience, which has been widely used in evaluation of quality of life in chronic diseases, clinical trials, adverse event monitoring and drug registration and approval in recent years. Rare diseases are a kind of diseases that seriously affect the physical function, mental health and quality of life of patients. Due to the lack of understanding of the natural history of rare diseases and the lack of sensitive biomarkers, patients' opinions and feelings are the key and ultimate goal of clinical decision making and intervention efficacy evaluation for rare diseases. At present, domestic research on PROs is just starting, and few involves in rare diseases. Therefore, this article reviewed the international definition, policy history and application status of PRO in rare diseases, and further discussed the existing challenges in the application of PRO in rare diseases, and looked forward to the application prospects of PRO in China.

  • Qi KANG, Hao YANG, Chunlin JIN
    World Clinical Drug. 2022, 43(2): 130-134.

    This study systematically reviews the overall situation of drug security for rare diseases in Shanghai, analyzes the existing problems, and expounds the value and feasibility of drug security for rare diseases. This study also proposes that under the new policy situation, Shanghai should give full play to the advantages of good economic foundation, strong social power and sufficient management experience, and actively explore a comprehensive drug security model of rare disease guided by the government, integrate resources of medical security, social assistance and charity support, and gather the strength of the whole society. It is necessary to accelerate the exploration of the establishment of a special fund for rare disease medication with government guidance and full participation of social forces. Improve drug security for rare diseases by stages, enhance supporting mechanism, support medical science and technology innovation, so as to provide reference for the country and other regions.

  • Qi KANG, Dingguo LI, Hao YANG, Chunlin JIN
    World Clinical Drug. 2022, 43(2): 135-139.

    For Gaucher Disease, a rare disease, which requires high-value medication for treatment, Shanghai has established a multi-tiered system consisting of the Basic Medical Insurance (BMI), the Shanghai Rare Disease Prevention and Control Foundation Lysosomal Storage Disease Special Aid Fund (SAF), and the Shanghai Primary and Secondary School Students, Infants and Children Hospitalization Medical Mutual Fund (CHMF) for insuring Gaucher Disease. This security system was the leading one in China at that time, and patients with Gaucher Disease in Shanghai could really have access to medicine. In order to understand the guarantee of high-value specific drugs for Gaucher Disease patients, this paper analyzed the cost-sharing situation of Gaucher Disease from 2018 to 2020, and found that the total cost for six patients was 36.35 millions Chinese Yuan (CNH), an average of 2.02 millions CNH for per person per year. Among the costs, the proportions of BMI, SAF and individual out-of-pocket rate were 79.02%, 16.28% and 4.70%, respectively. From the Shanghai coverage experience, it can be found that high-value drugs for rare diseases are very expensive, a high level of coverage is needed to ensure that patients actually have access to the drugs, and this often requires multiple parties to work together to establish a coverage mechanism.

  • Jinbao TA, Chao SONG, Liping WANG
    World Clinical Drug. 2022, 43(2): 140-143.
    Objective

    To explore the effect of micro RNA (miRNA, miR)-19a-3p on human leukemia forkhead protein O1 (FoxO1)-Kruppel-like factor (KLF)2- sphingosine-1-phosphate receptor 1 (S1P1) pathway.

    Methods

    Human leukemia T lymphocytes were selected for routinely subcultured and were divided into experimental group and control group. The expression of miR-19a-3p in the experimental group was knocked down by transfection small interfering RNA, but the control group did not do any stimulation. The expression level of miR-19a-3p, expression of FoxO1, KLF2, S1P1 in cells and the cell proliferation level were detected, and the expression of related indicators between the two groups were compared.

    Results

    After subculture, the expressions of miR-19a-3p in the two groups were (2.44±0.21) and (1.53±0.15), with statistical significance (P<0.05). After knockdown, the expression level of FoxO1 (35.33±0.89), KLF2 (1.92±0.48), S1P1 (1.45±0.15) in the experimental group were significantly higher than those in the control group FoxO1 (1.33±0.29), KLF2 (0.66±0.19), S1P1 (0.41±0.09), and the difference were statistically significant (P<0.05). There was no significant difference in cell proliferation between the two groups, but compared with the control group, the inhibition of cell apoptosis was lifted.

    Conclusion

    miR-19a-3p is highly expressed in lymphoma and has an inhibitory effect on the FoxO1-KLF2-S1P1 pathway. Inhibiting the high expression of miR-19a-3p is beneficial to activate the positive regulation of FoxO1-KLF2-S1P1 pathway.

  • Jinling LU, Shengjiao YAO, Na LIU
    World Clinical Drug. 2022, 43(2): 144-148.
    Objective

    To investigate the effects of goserelin on ovarian cyst in breast cancer patients with and the effects of ovarian stromal blood flow.

    Methods

    A total of 108 breast cancer patients with ovarian cyst caused by tamoxifen from March 2018 to February 2021 in Department of Obstetrics and Gynecology, Beijing No.6 Hospital were selected as the subjects. They were divided into the study group (n=56) and the control group (n=52) according to the lottery method. The control group was treated with routine chemotherapy, and the commonly used drug was mifepristone, and the study group received goserelin for 6 months. The curative effects, sex hormone levels, changes of ovarian stromal blood flow, prognosis and incidence of adverse drug reactions were compared between the two groups before and after treatment.

    Results

    After treatment, the total effective rate of the study group was higher than that of the control group [94.64% (53/56) vs 76.92% (40/52)](P<0.05). The levels of luteinizing hormone, follicle stimulating hormone and estradiol in the study group were lower than those in the control group [(7.58±1.60)U/L vs (9.76±1.23)U/L, (7.41±1.12)U/L vs (8.96±1.50)U/L, (83.50±6.49)pmol/L vs (98.72±7.34)pmol/L](P<0.05). The peak systolic velocity and end diastolic velocity in the study group were higher than those in the control group [(16.02±2.31)cm/s vs (15.02±2.12)cm/s, (5.51±1.01)cm/s vs (4.67±0.87)cm/s](P<0.05). The rate of dominant follicle formation and successful pregnancy in the study group was higher than those in the control group [82.14% (46/56) vs 59.61% (31/52), 69.64% (39/56) vs 44.23% (23/52)](P<0.05).

    Conclusion

    Goserelin has significant clinical effects on ovarian cyst. It can effectively improve the clinical symptoms, ovarian stromal blood flow and pregnancy rate, reduce the recurrence rate. It is safe and reliable and worthy of further promotion.

  • Qiuye CHEN, Liangyu WENG, Yanyun MA, Hong TANG
    World Clinical Drug. 2022, 43(2): 149-154.
    Objective

    To observe the clinical effects of Tiaozhi Jiangtang tablets on patients with type 2 diabetes mellitus (T2DM) patients with phlegm and blood stasis syndrome.

    Methods

    A total of 75 obesity T2DM patients with phlegm and blood stasis syndrome admitted to the Department of Endocrinology, LongHua Hospital Shanghai University of Traditional Chinese Medicine (TCM) from February 2018 to April 2019 were randomly divided into the treatment group (Tiaozhi Jiangtang tablets+metformin, n=40) and the control group (metformin, n=35). The treatment course was 12 weeks. The changes of clinical symptoms, blood glucose, insulin resistance, obesity and inflammatory cytokines were observed before and after treatment.

    Results

    The TCM syndrome score, fasting insulin, 2 h postprandial insulin, homeostasis model assessment of insulin resistance (HOME-IR), body mass index, waist circumference and interleukin-6 in the two groups were lower than those before treatment (P<0.05), and the treatment group was better than the control group (P<0.05). The levels of fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin in the two groups were lower than those before treatment (P<0.05), but there was no significant difference between the two groups (P>0.05). Compared with before treatment, tumor necrosis factor-α in the treatment group was decreased (P<0.05), but there was no significant difference in the control group (P>0.05). The total effective rate of TCM syndrome in the treatment group (85%) was better than that in the control group (62.86%)(P<0.05).

    Conclusion

    Tiaozhi Jiangtang tablets can improve the symptoms and signs, insulin resistance, obesity and inflammatory cytokine level of obesity T2DM patients with phlegm and blood stasis syndrome, which is worthy of further clinical promotion.

  • Jing HUANG, Shuyuan XIONG, Shenglan DING, Qingfeng CHENG, Zhiping LIU
    World Clinical Drug. 2022, 43(2): 155-163.
    Objective

    To evaluate the efficacy and safety of pentoxifylline (PTX) in the treatment of diabetic neuropathy (DN).

    Methods

    PubMed, Embase, Cochrane Library, Web of Science, Ovid, Chinese Biomedical Literature Database, VIP database, Wanfang database and China National Knowledge Internet were systematically searched to collect the sudies on the treatment of DN with PTX. The search duration was from the establishment of the database to December 10, 2019, and the languages were limited to Chinese and English. Two researchers independently screened the literature, evaluated the methodological quality of the included sudies, extracted the data, and then conducted qualitative analysis.

    Results

    A total of 16 original studies were included, with a total of 928 subjects. There were 11 randomized controlled trials and 5 quasi-randomized controlled trials. The main outcome indicators included in the study were hemorheology, nerve conduction velocity, current perception threshold, pain, Michigan neuropathy screening instrument, blood glucose, blood pressure, blood lipid, erectile function and adverse reactions.

    Conclusion

    PTX can increase erythrocyte deformability, reduce whole blood viscosity, plasma viscosity, maximum platelet aggregation rate, fibrinogen and erythrocyte aggregation index in patients with DN. It can be used as an adjuvant treatment for DN and is relatively safe.

  • Tingting GU, Yongchun YU, Dongmei WANG, Hongxiang FEI
    World Clinical Drug. 2022, 43(2): 164-168.
    Objective

    To observe the clinical effect of Xingan Tongzhi decoction in treating stable angina pectoris patients of coronary atherosclerotic heart disease (CHD) with Qi stagnation and blood stasis.

    Methods

    In a completely randomized, parallel controlled design, sixty-six cases of CHD stable angina pectoris diagnosed as Qi stagnation and blood stasis syndrome were included and randomly divided into treatment group and control group, 33 cases in each group. The two groups were based on conventional western medicine treatment for 8 weeks, and the treatment group was additionally treated with Xingan Tongzhi decoction. The frequency of angina pectoris attack was the main therapeutic index, and the changes of the traditional Chinese medicine (TCM) syndrome score and ECG were the secondary therapeutic indexes.

    Results

    After treatment, both groups can significantly improve the incidence of angina pectoris in CHD patients, and the treatment group was better than the control group (P<0.05). The total effective rate in the treatment group was 90.00%, which was higher than that in the control group (60.00%)(P<0.05). After treatment, the TCM syndromes of CHD patients with stable angina pectoris were significantly improved in both groups, and the treatment group was better than the control group (P<0.05). The total effective rate of the treatment group was 93.33%, which was higher than that in the control group (70.00%)(P<0.05). There was no statistical significance in ECG efficacy before and after treatment, and no local or systemic adverse reactions occurred during treatment.

    Conclusion

    Xingan Tongzhi decoction is quite effective in treating the stable angina pectoris of coronary heart disease with the syndrome of Qi stagnation and blood stasis. It can effectively reduce the frequency of angina pectoris in patients with good safety and is worthy of promotion.

News